COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00044187
Recruitment Status : Completed
First Posted : August 23, 2002
Last Update Posted : July 19, 2006
Information provided by:
Eli Lilly and Company

Brief Summary:

Olanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes with bipolar 1 disorder. This Anti-obesity Agent is currently marketed for the management of obesity. In this study, the Anti-obesity Agent is being tested to see if it can treat weight gain that may be associated with taking olanzapine.

The purposes of this study are to determine the safety of olanzapine when given in combination with the Anti-obesity Agent and any side effects that might be associated with it and whether weight-gain agent can help treat weight gain that may be associated with taking olanzapine.

Condition or disease Intervention/treatment Phase
Schizophrenia Psychotic Disorders Bipolar Disorder Drug: Sibutramine Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 130 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: The Assessment of a Anti-Obesity Agent for the Treatment of Olanzapine-Associated Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder and Bipolar I Disorder
Study Start Date : April 2001
Study Completion Date : September 2003

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Eligibility Criteria:

  • You must be between the ages of 18 and 65. If you have reached your 66th birthday, you will not be able to participate.
  • You must have been diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, or bipolar I disorder and be taking olanzapine.
  • You must be able to visit the doctor's office as scheduled for the next 4 months.

Exclusion Criteria:

  • You have a history of an illness that would cause weight loss or gain in the near future.
  • You have taken remoxipride within the past 6 months.
  • You are allergic to olanzapine or Anti-obesity Agent.
  • You have uncontrolled high blood pressure, congestive heart failure, or have had a stroke.
  • You have a serious medical illness, such as heart, liver, or kidney disease.
  • You are pregnant or breast feeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00044187

Layout table for location information
United States, California
El Centro, California, United States
United States, Florida
Jacksonville, Florida, United States
Miami, Florida, United States
United States, Idaho
Boise, Idaho, United States
United States, Illinois
Chicago, Illinois, United States
United States, Indiana
Indianapolis, Indiana, United States
Lafayette, Indiana, United States
United States, Kansas
Prairie Village, Kansas, United States
United States, Massachusetts
Milford, Massachusetts, United States
United States, New Jersey
Clementon, New Jersey, United States
United States, Ohio
Beachwood, Ohio, United States
United States, Tennessee
Johnson City, Tennessee, United States
Memphis, Tennessee, United States
United States, Texas
Houston, Texas, United States
United States, Virginia
Richmond, Virginia, United States
United States, Washington
Bellevue, Washington, United States
Sponsors and Collaborators
Eli Lilly and Company
Layout table for additonal information Identifier: NCT00044187    
Other Study ID Numbers: 5102
First Posted: August 23, 2002    Key Record Dates
Last Update Posted: July 19, 2006
Last Verified: July 2006
Keywords provided by Eli Lilly and Company:
schizoaffective disorder
schizophreniform disorder
bipolar I disorder
Additional relevant MeSH terms:
Layout table for MeSH terms
Weight Gain
Bipolar Disorder
Psychotic Disorders
Mental Disorders
Pathologic Processes
Body Weight
Schizophrenia Spectrum and Other Psychotic Disorders
Bipolar and Related Disorders
Body Weight Changes
Antidepressive Agents
Psychotropic Drugs
Appetite Depressants
Anti-Obesity Agents